[go: up one dir, main page]

MX384887B - Ensamblaje de adn mediado por nucleasa. - Google Patents

Ensamblaje de adn mediado por nucleasa.

Info

Publication number
MX384887B
MX384887B MX2021000857A MX2021000857A MX384887B MX 384887 B MX384887 B MX 384887B MX 2021000857 A MX2021000857 A MX 2021000857A MX 2021000857 A MX2021000857 A MX 2021000857A MX 384887 B MX384887 B MX 384887B
Authority
MX
Mexico
Prior art keywords
sequences
create
overlapping
complementary
nuclease
Prior art date
Application number
MX2021000857A
Other languages
English (en)
Other versions
MX2021000857A (es
Inventor
Andrew J Murphy
Caitlin Montagna
Chris Schoenherr
Corey Momont
David M Valenzuela
Gregg S Warshaw
John Mcwhirter
Jose F Rojas
Ka-Man Venus Lai
Lynn Macdonald
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of MX2021000857A publication Critical patent/MX2021000857A/es
Publication of MX384887B publication Critical patent/MX384887B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/66—General methods for inserting a gene into a vector to form a recombinant vector using cleavage and ligation; Use of non-functional linkers or adaptors, e.g. linkers containing the sequence for a restriction endonuclease
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C12N15/1031—Mutagenizing nucleic acids mutagenesis by gene assembly, e.g. assembly by oligonucleotide extension PCR
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/64—General methods for preparing the vector, for introducing it into the cell or for selecting the vector-containing host

Landscapes

  • Genetics & Genomics (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a métodos para ensamblar al menos dos ácidos nucleicos mediante el uso de un agente nucleasa específico de secuencias (p. ej., un complejo ARNg-Cas) para crear secuencias de extremo que tienen complementariedad y ensamblar posteriormente las secuencias complementarias superpuestas. El agente nucleasa (p. ej., un complejo ARNg-Cas) puede crear rupturas bicatenarias en el ADNbc con el propósito de crear secuencias de extremo superpuestas o puede crear mellas en cada cadena para producir secuencias de extremo salientes complementarias. El ensamblaje mediante el uso del método descrito en la presente descripción puede ensamblar cualquier ácido nucleico que tenga secuencias superpuestas o puede usar un acoplador oligo para ensamblar secuencias sin extremos complementarios.
MX2021000857A 2014-06-23 2015-06-23 Ensamblaje de adn mediado por nucleasa. MX384887B (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201462015809P 2014-06-23 2014-06-23
US201462016400P 2014-06-24 2014-06-24
US201462036983P 2014-08-13 2014-08-13
PCT/US2015/037199 WO2015200334A1 (en) 2014-06-23 2015-06-23 Nuclease-mediated dna assembly

Publications (2)

Publication Number Publication Date
MX2021000857A MX2021000857A (es) 2021-07-28
MX384887B true MX384887B (es) 2025-03-14

Family

ID=53525285

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2021000857A MX384887B (es) 2014-06-23 2015-06-23 Ensamblaje de adn mediado por nucleasa.
MX2016016905A MX379237B (es) 2014-06-23 2015-06-23 Ensamblaje de adn mediado por nucleasa.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2016016905A MX379237B (es) 2014-06-23 2015-06-23 Ensamblaje de adn mediado por nucleasa.

Country Status (25)

Country Link
US (6) US9738897B2 (es)
EP (3) EP3155099B1 (es)
JP (4) JP6336140B2 (es)
KR (2) KR102237151B1 (es)
CN (2) CN112029787B (es)
AU (3) AU2015280120B2 (es)
BR (1) BR112016030145A8 (es)
CA (1) CA2953499C (es)
CY (2) CY1120520T1 (es)
DK (2) DK3155099T3 (es)
ES (2) ES2781323T3 (es)
HR (1) HRP20200523T1 (es)
HU (1) HUE049405T2 (es)
IL (1) IL249612B (es)
LT (1) LT3354732T (es)
MX (2) MX384887B (es)
NZ (1) NZ765591A (es)
PL (2) PL3155099T3 (es)
PT (2) PT3155099T (es)
RS (1) RS60366B1 (es)
RU (1) RU2707911C2 (es)
SG (2) SG11201610481YA (es)
SI (1) SI3354732T1 (es)
SM (1) SMT202000174T1 (es)
WO (1) WO2015200334A1 (es)

Families Citing this family (107)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2734621B1 (en) 2011-07-22 2019-09-04 President and Fellows of Harvard College Evaluation and improvement of nuclease cleavage specificity
US20150044192A1 (en) 2013-08-09 2015-02-12 President And Fellows Of Harvard College Methods for identifying a target site of a cas9 nuclease
US9359599B2 (en) 2013-08-22 2016-06-07 President And Fellows Of Harvard College Engineered transcription activator-like effector (TALE) domains and uses thereof
US9388430B2 (en) 2013-09-06 2016-07-12 President And Fellows Of Harvard College Cas9-recombinase fusion proteins and uses thereof
US9526784B2 (en) 2013-09-06 2016-12-27 President And Fellows Of Harvard College Delivery system for functional nucleases
US9340800B2 (en) 2013-09-06 2016-05-17 President And Fellows Of Harvard College Extended DNA-sensing GRNAS
US9840699B2 (en) 2013-12-12 2017-12-12 President And Fellows Of Harvard College Methods for nucleic acid editing
US9738897B2 (en) 2014-06-23 2017-08-22 Regeneron Pharmaceuticals, Inc. Nuclease-mediated DNA assembly
WO2016007604A1 (en) * 2014-07-09 2016-01-14 Gen9, Inc. Compositions and methods for site-directed dna nicking and cleaving
WO2016022363A2 (en) 2014-07-30 2016-02-11 President And Fellows Of Harvard College Cas9 proteins including ligand-dependent inteins
CN107250148B (zh) 2014-12-03 2021-04-16 安捷伦科技有限公司 具有化学修饰的指导rna
WO2016109255A1 (en) * 2014-12-30 2016-07-07 University Of South Florida Methods and compositions for cloning into large vectors
WO2016164356A1 (en) 2015-04-06 2016-10-13 The Board Of Trustees Of The Leland Stanford Junior University Chemically modified guide rnas for crispr/cas-mediated gene regulation
KR102377189B1 (ko) 2015-05-29 2022-03-22 리제너론 파마슈티칼스 인코포레이티드 C9orf72 유전자좌에서 파괴를 갖는 비-인간 동물
IL258821B (en) 2015-10-23 2022-07-01 Harvard College Nucleobase editors and their uses
US11208649B2 (en) 2015-12-07 2021-12-28 Zymergen Inc. HTP genomic engineering platform
US9988624B2 (en) 2015-12-07 2018-06-05 Zymergen Inc. Microbial strain improvement by a HTP genomic engineering platform
KR20180084756A (ko) 2015-12-07 2018-07-25 지머젠 인코포레이티드 코리네박테리움 글루타미컴으로부터의 프로모터
IL302725A (en) 2016-01-13 2023-07-01 Regeneron Pharma Rodents having an engineered heavy chain diversity region
CN109640644B (zh) 2016-06-03 2021-10-26 瑞泽恩制药公司 表达外源末端脱氧核苷酸转移酶的非人动物
US10767175B2 (en) 2016-06-08 2020-09-08 Agilent Technologies, Inc. High specificity genome editing using chemically modified guide RNAs
EP3478833A4 (en) 2016-06-30 2019-10-02 Zymergen, Inc. METHOD FOR PRODUCING A BACTERIAL HEMOGLOBIN LIBRARY AND ITS USE
JP2019519241A (ja) 2016-06-30 2019-07-11 ザイマージェン インコーポレイテッド グルコース透過酵素ライブラリーを生成するための方法およびその使用
US20190330659A1 (en) * 2016-07-15 2019-10-31 Zymergen Inc. Scarless dna assembly and genome editing using crispr/cpf1 and dna ligase
US10548302B2 (en) 2016-07-29 2020-02-04 Regeneron Pharmaceuticals, Inc. Fibrillin-1 mutations for modeling neonatal progeroid syndrome with congenital lipodystrophy
KR20250103795A (ko) 2016-08-03 2025-07-07 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 아데노신 핵염기 편집제 및 그의 용도
CA3033327A1 (en) 2016-08-09 2018-02-15 President And Fellows Of Harvard College Programmable cas9-recombinase fusion proteins and uses thereof
WO2018039438A1 (en) 2016-08-24 2018-03-01 President And Fellows Of Harvard College Incorporation of unnatural amino acids into proteins using base editing
WO2018048827A1 (en) * 2016-09-07 2018-03-15 Massachusetts Institute Of Technology Rna-guided endonuclease-based dna assembly
CA3037185A1 (en) 2016-09-15 2018-03-22 ArcherDX, Inc. Methods of nucleic acid sample preparation
US10683531B2 (en) 2016-09-15 2020-06-16 ArcherDX, Inc. Methods of nucleic acid sample preparation for analysis of cell-free DNA
EP3518667B1 (en) * 2016-09-30 2024-10-30 Regeneron Pharmaceuticals, Inc. Rodents having a hexanucleotide repeat expansion in a c9orf72 locus
JP7588390B2 (ja) 2016-10-14 2024-11-22 プレジデント アンド フェローズ オブ ハーバード カレッジ 核酸塩基エディターのａａｖ送達
CA3042391A1 (en) * 2016-11-02 2018-05-11 ArcherDX, Inc. Methods of nucleic acid sample preparation for immune repertoire sequencing
CA3038720A1 (en) 2016-11-04 2018-07-12 Regeneron Pharmaceuticals, Inc. Non-human animals having an engineered immunoglobulin lambda light chain locus
TWI835719B (zh) 2016-12-08 2024-03-21 美商英特利亞醫療公司 經修飾之嚮導rna
WO2018119359A1 (en) 2016-12-23 2018-06-28 President And Fellows Of Harvard College Editing of ccr5 receptor gene to protect against hiv infection
TW201839136A (zh) 2017-02-06 2018-11-01 瑞士商諾華公司 治療血色素異常症之組合物及方法
JP2020507312A (ja) * 2017-02-10 2020-03-12 ザイマージェン インコーポレイテッド 複数の宿主用の複数のｄｎａコンストラクトのアセンブリ及び編集のためのモジュラーユニバーサルプラスミド設計戦略
CN110662556A (zh) 2017-03-09 2020-01-07 哈佛大学的校长及成员们 癌症疫苗
WO2018165504A1 (en) 2017-03-09 2018-09-13 President And Fellows Of Harvard College Suppression of pain by gene editing
JP2020510439A (ja) 2017-03-10 2020-04-09 プレジデント アンド フェローズ オブ ハーバード カレッジ シトシンからグアニンへの塩基編集因子
BR112019019655A2 (pt) 2017-03-23 2020-04-22 Harvard College editores de nucleobase que compreendem proteínas de ligação a dna programáveis por ácido nucleico
WO2018209320A1 (en) 2017-05-12 2018-11-15 President And Fellows Of Harvard College Aptazyme-embedded guide rnas for use with crispr-cas9 in genome editing and transcriptional activation
WO2018222941A1 (en) * 2017-06-01 2018-12-06 Counsyl, Inc. Preparation of concatenated polynucleotides
IL271205B2 (en) 2017-06-12 2025-02-01 Twist Bioscience Corp Methods for assembling continuous nucleic acids
US10081829B1 (en) * 2017-06-13 2018-09-25 Genetics Research, Llc Detection of targeted sequence regions
CN111094573A (zh) * 2017-07-12 2020-05-01 梅约医学教育与研究基金会 有效靶向敲入或基因置换的材料和方法
JP2020534795A (ja) 2017-07-28 2020-12-03 プレジデント アンド フェローズ オブ ハーバード カレッジ ファージによって支援される連続的進化（ｐａｃｅ）を用いて塩基編集因子を進化させるための方法および組成物
JP2020533957A (ja) 2017-07-31 2020-11-26 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Ｃｒｉｓｐｒリポーター非ヒト動物およびその使用
WO2019028032A1 (en) 2017-07-31 2019-02-07 Regeneron Pharmaceuticals, Inc. EMBRYONIC STEM CELLS OF TRANSGENIC MOUSE CASES AND MICE AND USES THEREOF
CN111247247A (zh) * 2017-08-21 2020-06-05 国立大学法人德岛大学 使用核苷酸靶识别的靶序列特异性改变技术
US11319532B2 (en) 2017-08-30 2022-05-03 President And Fellows Of Harvard College High efficiency base editors comprising Gam
EP3678680A4 (en) 2017-09-05 2021-12-01 Regeneron Pharmaceuticals, Inc. ADMINISTRATION OF A GENE EDITING SYSTEM CONTAINING A SINGLE RETROVIRAL PARTICLE AND METHODS OF GENERATION AND USE
EP3585162B1 (en) 2017-09-29 2023-08-30 Regeneron Pharmaceuticals, Inc. Rodents comprising a humanized ttr locus and methods of use
KR20250107288A (ko) 2017-10-16 2025-07-11 더 브로드 인스티튜트, 인코퍼레이티드 아데노신 염기 편집제의 용도
CA3076377A1 (en) 2017-11-30 2019-06-06 Regeneron Pharmaceuticals, Inc. Non-human animals comprising a humanized trkb locus
SG11202003044SA (en) 2017-12-05 2020-04-29 Regeneron Pharma Non-human animals having an engineered immunoglobulin lambda light chain and uses thereof
WO2019118949A1 (en) 2017-12-15 2019-06-20 The Broad Institute, Inc. Systems and methods for predicting repair outcomes in genetic engineering
CN116349651A (zh) 2018-03-19 2023-06-30 瑞泽恩制药公司 使用crispr/cas系统对动物进行转录调制
CA3093850A1 (en) 2018-03-26 2019-10-03 Regeneron Pharmaceuticals, Inc. Humanized rodents for testing therapeutic agents
AU2019255725A1 (en) * 2018-04-18 2020-12-10 Ligandal, Inc. Methods and compositions for genome editing
WO2019217785A1 (en) * 2018-05-10 2019-11-14 St. Jude Children's Research Hospital, Inc. High-throughput method for characterizing the genome-wide activity of editing nucleases in vitro
WO2019213910A1 (en) * 2018-05-10 2019-11-14 Syngenta Participations Ag Methods and compositions for targeted editing of polynucleotides
WO2019226953A1 (en) 2018-05-23 2019-11-28 The Broad Institute, Inc. Base editors and uses thereof
IL318469A (en) 2018-06-14 2025-03-01 Regeneron Pharma Non-human animals capable of reorganizing transgenic DH-DH, and their uses
CN112703250A (zh) * 2018-08-15 2021-04-23 齐默尔根公司 CRISPRi在高通量代谢工程中的应用
WO2020092453A1 (en) 2018-10-29 2020-05-07 The Broad Institute, Inc. Nucleobase editors comprising geocas9 and uses thereof
CN113423831B (zh) 2018-12-20 2023-03-10 瑞泽恩制药公司 核酸酶介导的重复扩增
EP3908291A4 (en) 2019-01-07 2023-01-11 Dana-Farber Cancer Institute, Inc. VON HIPPEL-LINDAU (VHL) E3 UBIQUITIN LIGASE RECRUITMENT AGENTS FOR FKBP12 SMALL MOLECULES DEGRADATION AND USES IN DTAG SYSTEMS
US12351837B2 (en) 2019-01-23 2025-07-08 The Broad Institute, Inc. Supernegatively charged proteins and uses thereof
EP3942042A1 (en) 2019-03-19 2022-01-26 The Broad Institute, Inc. Methods and compositions for editing nucleotide sequences
CN117178959A (zh) 2019-04-04 2023-12-08 瑞泽恩制药公司 包括人源化凝血因子12基因座的非人动物
IL286917B (en) 2019-04-04 2022-09-01 Regeneron Pharma Methods for scarless introduction of targeted modifications into targeting vectors
EP3956349A1 (en) 2019-04-17 2022-02-23 The Broad Institute, Inc. Adenine base editors with reduced off-target effects
GB201905651D0 (en) * 2019-04-24 2019-06-05 Lightbio Ltd Nucleic acid constructs and methods for their manufacture
EP3966324A1 (en) * 2019-05-06 2022-03-16 DSM IP Assets B.V. Multipartite crispr donor
AU2020286382A1 (en) 2019-06-04 2021-11-04 Regeneron Pharmaceuticals, Inc. Non-human animals comprising a humanized TTR locus with a beta-slip mutation and methods of use
SG11202111258TA (en) 2019-06-05 2021-11-29 Regeneron Pharma Non-human animals having a limited lambda light chain repertoire expressed from the kappa locus and uses thereof
MX2021015122A (es) 2019-06-07 2022-04-06 Regeneron Pharma Animales no humanos que comprenden un locus de albumina humanizado.
WO2020264016A1 (en) 2019-06-25 2020-12-30 Inari Agriculture, Inc. Improved homology dependent repair genome editing
CN112175939A (zh) * 2019-07-03 2021-01-05 华大青兰生物科技(无锡)有限公司 一种基于同源序列的核酸拼接方法及其应用
GB201913898D0 (en) * 2019-09-26 2019-11-13 Lightbio Ltd Nucleic acid construct
US12435330B2 (en) 2019-10-10 2025-10-07 The Broad Institute, Inc. Methods and compositions for prime editing RNA
WO2021108363A1 (en) 2019-11-25 2021-06-03 Regeneron Pharmaceuticals, Inc. Crispr/cas-mediated upregulation of humanized ttr allele
CN115335521A (zh) * 2019-11-27 2022-11-11 克里斯珀医疗股份公司 合成rna分子的方法
US20230091690A1 (en) * 2019-12-30 2023-03-23 The Broad Institute, Inc. Guided excision-transposition systems
WO2021154791A1 (en) 2020-01-28 2021-08-05 Regeneron Pharmaceuticals, Inc. Non-human animals comprising a humanized pnpla3 locus and methods of use
EP4099821A1 (en) 2020-02-07 2022-12-14 Regeneron Pharmaceuticals, Inc. <smallcaps/>? ? ?klkb1? ? ? ? ?non-human animals comprising a humanizedlocus and methods of use
CN111334523A (zh) * 2020-03-13 2020-06-26 天津大学 一种大尺度dna的体内多轮迭代组装方法
EP4125348A1 (en) 2020-03-23 2023-02-08 Regeneron Pharmaceuticals, Inc. Non-human animals comprising a humanized ttr locus comprising a v30m mutation and methods of use
WO2021226558A1 (en) 2020-05-08 2021-11-11 The Broad Institute, Inc. Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence
IL303868A (en) 2020-12-23 2023-08-01 Regeneron Pharma Nucleic acids encoding anchor-modified antibodies and uses thereof
US20240141399A1 (en) * 2021-03-01 2024-05-02 The Regents Of The University Of California Methods for generating a crispr array
US11884915B2 (en) 2021-09-10 2024-01-30 Agilent Technologies, Inc. Guide RNAs with chemical modification for prime editing
CN113782103B (zh) * 2021-10-26 2024-07-09 大连大学 一种基于组合式酶切机制的dna矩阵处理方法
CN118251491A (zh) 2021-10-28 2024-06-25 瑞泽恩制药公司 用于敲除C5的CRISPR/Cas相关方法及组合物
CN118632622A (zh) 2021-12-08 2024-09-10 瑞泽恩制药公司 突变型肌纤蛋白疾病模型及其用途
EP4473118A1 (en) * 2022-01-31 2024-12-11 Integrated DNA Technologies, Inc. Recombination-based dna assembly methods and compositions
EP4475671A1 (en) 2022-02-07 2024-12-18 Regeneron Pharmaceuticals, Inc. Compositions and methods for defining optimal treatment timeframes in lysosomal disease
EP4476245A1 (en) 2022-02-11 2024-12-18 Regeneron Pharmaceuticals, Inc. Compositions and methods for screening 4r tau targeting agents
WO2023235725A2 (en) 2022-05-31 2023-12-07 Regeneron Pharmaceuticals, Inc. Crispr-based therapeutics for c9orf72 repeat expansion disease
US20240224964A9 (en) 2022-09-29 2024-07-11 Regeneron Pharmaceuticals, Inc. Correction of hepatosteatosis in humanized liver animals through restoration of il6/il6r/gp130 signaling in human hepatocytes
WO2025015224A2 (en) * 2023-07-12 2025-01-16 BioSpyder Technologies, Inc. Treatment of samples containing nucleic acids
CN117904069B (zh) * 2024-01-04 2025-07-15 华中农业大学 VirEN蛋白介导的DNA拼接和基因编辑方法
CN117987436B (zh) * 2024-04-03 2024-06-25 南京鸿明生物科技有限公司 一种双链靶dna序列的制备方法
WO2025250495A1 (en) 2024-05-28 2025-12-04 Regeneron Pharmaceuticals, Inc. Acceleration of human hepatocyte engraftment in humanized liver animals by supplementing paracrine ligands or agonists that activate human liver regeneration signals

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6312892B1 (en) 1996-07-19 2001-11-06 Cornell Research Foundation, Inc. High fidelity detection of nucleic acid differences by ligase detection reaction
US6599692B1 (en) 1999-09-14 2003-07-29 Sangamo Bioscience, Inc. Functional genomics using zinc finger proteins
US20030104526A1 (en) 1999-03-24 2003-06-05 Qiang Liu Position dependent recognition of GNN nucleotide triplets by zinc fingers
US20050144655A1 (en) 2000-10-31 2005-06-30 Economides Aris N. Methods of modifying eukaryotic cells
US7105348B2 (en) 2000-10-31 2006-09-12 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6586251B2 (en) 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
JP2004537260A (ja) 2000-12-07 2004-12-16 サンガモ バイオサイエンシーズ， インコーポレイテッド ジンクフィンガータンパク質による血管新生の調節
CA2435394C (en) 2001-01-22 2018-01-09 Sangamo Biosciences, Inc. Modified zinc finger binding proteins
WO2002057308A2 (en) 2001-01-22 2002-07-25 Sangamo Biosciences, Inc. Zinc finger polypeptides and their use
EP1476547B1 (en) 2002-01-23 2006-12-06 The University of Utah Research Foundation Targeted chromosomal mutagenesis using zinc finger nucleases
EP1485475B2 (en) 2002-03-15 2017-09-20 Cellectis Hybrid and single chain meganucleases and use thereof
AU2003218382B2 (en) 2002-03-21 2007-12-13 Sangamo Therapeutics, Inc. Methods and compositions for using zinc finger endonucleases to enhance homologous recombination
EP1581610A4 (en) 2002-09-05 2009-05-27 California Inst Of Techn USE OF CHIMERIC NUCLEASES TO STIMULATE GEN-TARGETING
WO2004031346A2 (en) 2002-09-06 2004-04-15 Fred Hutchinson Cancer Research Center Methods and compositions concerning designed highly-specific nucleic acid binding proteins
US7888121B2 (en) 2003-08-08 2011-02-15 Sangamo Biosciences, Inc. Methods and compositions for targeted cleavage and recombination
US8409861B2 (en) 2003-08-08 2013-04-02 Sangamo Biosciences, Inc. Targeted deletion of cellular DNA sequences
EP1591521A1 (en) 2004-04-30 2005-11-02 Cellectis I-Dmo I derivatives with enhanced activity at 37 degrees C and use thereof
US20060063231A1 (en) 2004-09-16 2006-03-23 Sangamo Biosciences, Inc. Compositions and methods for protein production
WO2006097784A1 (en) 2005-03-15 2006-09-21 Cellectis I-crei meganuclease variants with modified specificity, method of preparation and uses thereof
WO2006097854A1 (en) 2005-03-15 2006-09-21 Cellectis Heterodimeric meganucleases and use thereof
MX2009006303A (es) 2006-12-14 2009-10-21 Dow Agrosciences Llc Proteinas de dedo de zinc no canonicas optimizadas.
CA2715586C (en) * 2008-02-15 2018-08-28 Synthetic Genomics, Inc. Methods for in vitro joining and combinatorial assembly of nucleic acid molecules
EP2206723A1 (en) 2009-01-12 2010-07-14 Bonas, Ulla Modular DNA-binding domains
US20110239315A1 (en) 2009-01-12 2011-09-29 Ulla Bonas Modular dna-binding domains and methods of use
WO2010107493A2 (en) 2009-03-20 2010-09-23 Sangamo Biosciences, Inc. Modification of cxcr4 using engineered zinc finger proteins
US8772008B2 (en) 2009-05-18 2014-07-08 Sangamo Biosciences, Inc. Methods and compositions for increasing nuclease activity
US20120178647A1 (en) 2009-08-03 2012-07-12 The General Hospital Corporation Engineering of zinc finger arrays by context-dependent assembly
WO2011020005A1 (en) 2009-08-14 2011-02-17 Regeneron Pharmaceuticals, Inc. miRNA-REGULATED DIFFERENTIATION-DEPENDENT SELF-DELETING CASSETTE
TR201903376T4 (tr) 2009-10-29 2019-04-22 Regeneron Pharma Çok fonksiyonlu alleller.
NO2510096T3 (es) 2009-12-10 2015-03-21
WO2011101696A1 (en) 2010-02-18 2011-08-25 Cellectis Improved meganuclease recombination system
GB201009732D0 (en) 2010-06-10 2010-07-21 Gene Bridges Gmbh Direct cloning
US9689012B2 (en) 2010-10-12 2017-06-27 Cornell University Method of dual-adapter recombination for efficient concatenation of multiple DNA fragments in shuffled or specified arrangements
US9637739B2 (en) 2012-03-20 2017-05-02 Vilnius University RNA-directed DNA cleavage by the Cas9-crRNA complex
WO2013141680A1 (en) 2012-03-20 2013-09-26 Vilnius University RNA-DIRECTED DNA CLEAVAGE BY THE Cas9-crRNA COMPLEX
SI3401400T1 (sl) 2012-05-25 2019-10-30 Univ California Postopki in sestavki za RNA usmerjeno modifikacijo tarčne DNA in za RNA usmerjeno modulacijo prepisovanja
SG11201503059XA (en) 2012-10-23 2015-06-29 Toolgen Inc Composition for cleaving a target dna comprising a guide rna specific for the target dna and cas protein-encoding nucleic acid or cas protein, and use thereof
EP3138911B1 (en) * 2012-12-06 2018-12-05 Sigma Aldrich Co. LLC Crispr-based genome modification and regulation
BR112015013784A2 (pt) 2012-12-12 2017-07-11 Massachusetts Inst Technology aplicação, manipulação e otimização de sistemas, métodos e composições para manipulação de sequência e aplicações terapêuticas
US8697359B1 (en) 2012-12-12 2014-04-15 The Broad Institute, Inc. CRISPR-Cas systems and methods for altering expression of gene products
DK3553174T3 (da) 2012-12-17 2025-08-04 Harvard College Rna-guided modificering af humant genom
EP2922393B2 (en) 2013-02-27 2022-12-28 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Gene editing in the oocyte by cas9 nucleases
US10612043B2 (en) 2013-03-09 2020-04-07 Agilent Technologies, Inc. Methods of in vivo engineering of large sequences using multiple CRISPR/cas selections of recombineering events
JP2016522679A (ja) 2013-04-04 2016-08-04 プレジデント アンド フェローズ オブ ハーバード カレッジ ＣＲＩＳＰＲ／Ｃａｓ系を用いたゲノム編集の治療的使用
US10421957B2 (en) 2013-07-29 2019-09-24 Agilent Technologies, Inc. DNA assembly using an RNA-programmable nickase
ES2844174T3 (es) 2013-09-18 2021-07-21 Kymab Ltd Métodos, células y organismos
AU2014368982B2 (en) 2013-12-19 2021-03-25 Amyris, Inc. Methods for genomic integration
WO2015116686A1 (en) 2014-01-29 2015-08-06 Agilent Technologies, Inc. Cas9-based isothermal method of detection of specific dna sequence
JP2016006930A (ja) 2014-06-20 2016-01-14 ソニー株式会社 撮像装置および撮像方法
US9738897B2 (en) 2014-06-23 2017-08-22 Regeneron Pharmaceuticals, Inc. Nuclease-mediated DNA assembly
WO2016007604A1 (en) 2014-07-09 2016-01-14 Gen9, Inc. Compositions and methods for site-directed dna nicking and cleaving
US20160053272A1 (en) 2014-07-18 2016-02-25 Whitehead Institute For Biomedical Research Methods Of Modifying A Sequence Using CRISPR
CN107429241B (zh) 2014-08-14 2025-10-24 百奥赛图(北京)医药科技股份有限公司 Dna敲入系统
CA2958082A1 (en) 2014-08-25 2016-03-03 Curza Global, Llc Method of producing n-alkyl polyamines
CN113584015B (zh) 2014-08-27 2025-05-02 新英格兰生物实验室公司 合成子的形成
CN104357438B (zh) * 2014-09-23 2020-04-24 中国科学院天津工业生物技术研究所 一种dna组装和克隆的方法
US10221398B2 (en) 2014-12-16 2019-03-05 C3J Therapeutics, Inc. Compositions of and methods for in vitro viral genome engineering
WO2016109255A1 (en) 2014-12-30 2016-07-07 University Of South Florida Methods and compositions for cloning into large vectors
WO2016130697A1 (en) 2015-02-11 2016-08-18 Memorial Sloan Kettering Cancer Center Methods and kits for generating vectors that co-express multiple target molecules
US20190330659A1 (en) 2016-07-15 2019-10-31 Zymergen Inc. Scarless dna assembly and genome editing using crispr/cpf1 and dna ligase
WO2018048827A1 (en) 2016-09-07 2018-03-15 Massachusetts Institute Of Technology Rna-guided endonuclease-based dna assembly

Also Published As

Publication number Publication date
US20160115486A1 (en) 2016-04-28
AU2015280120B2 (en) 2017-05-25
SG10201803444YA (en) 2018-06-28
US9580715B2 (en) 2017-02-28
MX2021000857A (es) 2021-07-28
CN106715694B (zh) 2020-10-20
US20190194668A1 (en) 2019-06-27
EP3354732B1 (en) 2020-01-08
CA2953499C (en) 2023-10-24
PL3155099T3 (pl) 2018-08-31
CN106715694A (zh) 2017-05-24
US20180002708A1 (en) 2018-01-04
ES2781323T3 (es) 2020-09-01
DK3354732T3 (da) 2020-04-06
MX379237B (es) 2025-03-10
AU2019200094A1 (en) 2019-01-31
WO2015200334A4 (en) 2016-03-17
KR102237151B1 (ko) 2021-04-07
SMT202000174T1 (it) 2020-05-08
AU2017213564A1 (en) 2017-08-31
US20240229048A1 (en) 2024-07-11
KR101822902B1 (ko) 2018-01-30
DK3155099T3 (en) 2018-05-07
RS60366B1 (sr) 2020-07-31
RU2017101329A3 (es) 2019-02-15
US20200208161A1 (en) 2020-07-02
JP6737974B1 (ja) 2020-08-12
LT3354732T (lt) 2020-04-10
CY1122962T1 (el) 2021-10-29
ES2666179T3 (es) 2018-05-03
PT3155099T (pt) 2018-04-20
KR20180011858A (ko) 2018-02-02
CA2953499A1 (en) 2015-12-30
US9738897B2 (en) 2017-08-22
EP3708663A1 (en) 2020-09-16
CN112029787A (zh) 2020-12-04
PT3354732T (pt) 2020-04-02
KR20170020505A (ko) 2017-02-22
JP2020120662A (ja) 2020-08-13
HUE049405T2 (hu) 2020-09-28
HRP20200523T1 (hr) 2020-08-07
HK1256688A1 (en) 2019-10-04
JP2020202836A (ja) 2020-12-24
AU2015280120A1 (en) 2017-01-19
NZ727952A (en) 2021-11-26
CN112029787B (zh) 2024-07-19
PL3354732T3 (pl) 2020-06-15
US10626402B2 (en) 2020-04-21
EP3354732A1 (en) 2018-08-01
RU2707911C2 (ru) 2019-12-02
MX2016016905A (es) 2017-08-10
IL249612B (en) 2021-04-29
CY1120520T1 (el) 2019-07-10
JP6684241B2 (ja) 2020-04-22
US10273488B2 (en) 2019-04-30
AU2017213564B2 (en) 2018-10-18
RU2017101329A (ru) 2018-07-24
IL249612A0 (en) 2017-02-28
EP3155099A1 (en) 2017-04-19
SG11201610481YA (en) 2017-01-27
NZ765591A (en) 2022-09-30
US20150376628A1 (en) 2015-12-31
US11932859B2 (en) 2024-03-19
BR112016030145A2 (pt) 2018-02-20
BR112016030145A8 (pt) 2018-12-11
JP7058306B2 (ja) 2022-04-21
SI3354732T1 (sl) 2020-07-31
JP2017518757A (ja) 2017-07-13
JP6336140B2 (ja) 2018-06-06
JP2017113031A (ja) 2017-06-29
EP3155099B1 (en) 2018-03-21
AU2019200094B2 (en) 2021-06-24
WO2015200334A1 (en) 2015-12-30

Similar Documents

Publication Publication Date Title
MX384887B (es) Ensamblaje de adn mediado por nucleasa.
CY1125029T1 (el) Τροποποιημενοι νουκλεοζιτες, νουκλεοτιδια, και νουκλεϊκα οξεα και χρησεις αυτων
DK3821011T3 (da) Transposom-aktiveret dna/rna-sekventering (ted rna-seq)
DK3348636T3 (da) Fremgangsmåde til modificering af en genomsekvens, der specifikt omdanner nukleobasen af en targetteret DNA-sekvens, og molekylær sekvens anvendt i fremgangsmåden
ZA201905536B (en) Methods for providing single-stranded rna
LT3701959T (lt) Rnr replikonas, skirtas įvairiapusiškai ir efektyviai genų raiškai
GB2598497B (en) Nucleic acid hybridization methods
IL259788A (en) Adapter nucleic acid sequences, compositions comprising same and methods for duplex sequencing using same
JP2015133993A5 (es)
IL259148B (en) Engineered nucleic acid targeted nucleic acids
HUE063813T2 (hu) CRISPR hibrid DNS/RNS polinukleotidok és alkalmazási eljárások
EP3645712A4 (en) T7 RNA POLYMERASE VARIANTS
IL284447B1 (en) Dux4 RNA silencing using RNA-targeted CRISPR-Cas13b
MX2017016688A (es) Nuevas enzimas y sistemas crispr.
WO2015196128A3 (en) Alternative nucleic acid molecules and uses thereof
HK1252166A1 (zh) 从环状rna产生环状dna的方法
IL254000B (en) Nucleic acid sequence composition
EP3303585A4 (en) Dna editing using single-stranded dna
EP3645711A4 (en) T7 RNA POLYMERASE VARIANTS
EP3696269A4 (en) SINGLE STRAND NUCLEIC ACID MOLECULE AND ITS PRODUCTION PROCESS
IL277346A (en) A method for creating a hairpin single-helical RNA molecule
IL273245A (en) RNA molecules
CY1120997T1 (el) Πρωτεϊνες συντηξης uti
EP3418289A4 (en) ARTIFICIAL NUCLEOSIDE AND ARTIFICIAL NUCLEOTIDE AND ARTIFICIAL OLIGONUCLEOTIDE
DK3190184T3 (da) Forbehandlingsfremgangsmåde og nukleinsyreekstraktionskit, der anvendes i fremgangsmåden